Proteins as binding targets of isothiocyanates in cancer prevention

Carcinogenesis. 2011 Oct;32(10):1405-13. doi: 10.1093/carcin/bgr111. Epub 2011 Jun 10.

Abstract

Isothiocyanates are versatile cancer-preventive compounds. Evidence from animal studies indicates that the anticarcinogenic activities of ITCs involve all the major stages of tumor growth: initiation, promotion and progression. Epidemiological studies have also shown that dietary intake of ITCs is associated with reduced risk of certain human cancers. A number of mechanisms have been proposed for the chemopreventive activities of ITCs. To identify the molecular targets of ITCs is a first step to understand the molecular mechanisms of ITCs. Studies in recent years have shown that the covalent binding to certain protein targets by ITCs seems to play an important role in ITC-induced apoptosis and cell growth inhibition and other cellular effects. The knowledge gained from these studies may be used to guide future design and screen of better and more efficacious compounds. In this review, we intend to cover all potential protein targets of ITCs so far studied and summarize what are known about their binding sites and the potential biological consequences. In the end, we also offer discussions to shed light onto the relationship between protein binding and reactive oxygen species generation by ITCs.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Animals
  • Anticarcinogenic Agents / metabolism
  • Anticarcinogenic Agents / therapeutic use*
  • Humans
  • Isothiocyanates / metabolism
  • Isothiocyanates / therapeutic use*
  • Neoplasms / metabolism
  • Neoplasms / prevention & control*
  • Protein Binding
  • Proteins / metabolism*

Substances

  • Anticarcinogenic Agents
  • Isothiocyanates
  • Proteins